Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DSM Chinese investment

This article was originally published in The Tan Sheet

Executive Summary

Nutritional and drug ingredient manufacturer Royal DSM agrees to acquire a 10 percent stake in North China Pharmaceutical Group Corporation Ltd. and to establish a joint venture to manufacture vitamin C products. The Netherlands-based DSM says March 19 it will have a 30 percent stake in the vitamin C joint venture, plus 51 percent ownership of separate partnerships with the Hebei Province-based Chinese firm to develop active and intermediate pharmaceutical ingredients for anti-infective drugs. DSM's total cash investment will amount to approximately $110 million in the agreements the firms expect to start implementing in the second half of 2009

You may also be interested in...



Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared

Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.

UK Responsible Person, EU ARs and Northern Ireland: The View From MedTech Europe

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel